MovDisordV3, PascalFrancis, Corpus, bibRecord, 002C07

Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's Disease

Identifieur interne : 002C07 ( PascalFrancis/Corpus ); précédent : 002C06; suivant : 002C08

Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's Disease

Auteurs : R. A. Hauser ; W. C. Koller ; J. P. Hubble ; T. Malapira ; K. Busenbark ; C. W. Olanow

Source :

Movement disorders [ 0885-3185 ] ; 2000.

RBID : Pascal:00-0269467

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Lévodopa, Antiparkinsonien, Carbidopa, Bromocriptine, Arrêt traitement, Chimiothérapie, Evolution, Homme, Ergot dérivé.

English descriptors

KwdEn :
- Antiparkinson agent, Bromocriptine, Carbidopa, Chemotherapy, Ergot derivatives, Evolution, Human, Levodopa, Parkinson disease, Treatment withdrawal.

Abstract

Putative neuroprotective agents for Parkinson's disease can be assessed in untreated patients using progression of clinical disability as an index of disease progression. To avoid the confound associated with symptomatic therapy, progression of the underlying disease can be assessed by evaluating the progression of clinical disability from an untreated baseline to a final visit following wash-out of symptomatic medication. In this type of analysis it is critical to use a wash-out of sufficient duration to ensure elimination of symptomatic effects. To assess the time course of resolution of symptomatic effects, we evaluated 31 patients at days 1, 8, and 15 following discontinuation of levodopa/carbidopa and bromocriptine. Mean total Unified Parkinson's Disease Rating Scale scores (± standard error) increased (worsened) by 7.4 ± 1.5 from day 1 to day 15 (p <0.0001), 4.5 ± 1.2 from day I to day 8 (p = 0.0009), and 2.9 ± 1.0 from day 8 to day 15 (p = 0.01). We conclude that a wash-out of at least 2 weeks is required to eliminate the symptomatic effects of levodopa/carbidopa and bromocriptine in patients with early Parkinson's disease.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 15`
A06				`@2 3`
A08	`01`	`1`	`ENG`	`@1 Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's Disease`
A11	`01`	`1`		`@1 HAUSER (R. A.)`
A11	`02`	`1`		`@1 KOLLER (W. C.)`
A11	`03`	`1`		`@1 HUBBLE (J. P.)`
A11	`04`	`1`		`@1 MALAPIRA (T.)`
A11	`05`	`1`		`@1 BUSENBARK (K.)`
A11	`06`	`1`		`@1 OLANOW (C. W.)`
A14	`01`			`@1 University of South Florida @2 Tampa, Florida @3 USA @Z 1 aut. @Z 4 aut.`
A14	`02`			`@1 University of Miami @2 Miami, Florida @3 USA @Z 2 aut.`
A14	`03`			`@1 Ohio State University @2 Columbus, Ohio @3 USA @Z 3 aut.`
A14	`04`			`@1 University of Kansas @2 Kansas City, Kansas @3 USA @Z 5 aut.`
A14	`05`			`@1 Mount Sinai School of Medicine @2 New York, NY @3 USA @Z 6 aut.`
A20				`@1 485-489`
A21				`@1 2000`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000087348900090`
A44				`@0 0000 @1 © 2000 INIST-CNRS. All rights reserved.`
A45				`@0 17 ref.`
A47	`01`	`1`		`@0 00-0269467`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Putative neuroprotective agents for Parkinson's disease can be assessed in untreated patients using progression of clinical disability as an index of disease progression. To avoid the confound associated with symptomatic therapy, progression of the underlying disease can be assessed by evaluating the progression of clinical disability from an untreated baseline to a final visit following wash-out of symptomatic medication. In this type of analysis it is critical to use a wash-out of sufficient duration to ensure elimination of symptomatic effects. To assess the time course of resolution of symptomatic effects, we evaluated 31 patients at days 1, 8, and 15 following discontinuation of levodopa/carbidopa and bromocriptine. Mean total Unified Parkinson's Disease Rating Scale scores (± standard error) increased (worsened) by 7.4 ± 1.5 from day 1 to day 15 (p <0.0001), 4.5 ± 1.2 from day I to day 8 (p = 0.0009), and 2.9 ± 1.0 from day 8 to day 15 (p = 0.01). We conclude that a wash-out of at least 2 weeks is required to eliminate the symptomatic effects of levodopa/carbidopa and bromocriptine in patients with early Parkinson's disease.
C02	`01`	`X`		`@0 002B02B06`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Parkinson maladie @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @5 01`
C03	`02`	`X`	`FRE`	`@0 Lévodopa @5 04`
C03	`02`	`X`	`ENG`	`@0 Levodopa @5 04`
C03	`02`	`X`	`SPA`	`@0 Levodopa @5 04`
C03	`03`	`X`	`FRE`	`@0 Antiparkinsonien @5 05`
C03	`03`	`X`	`ENG`	`@0 Antiparkinson agent @5 05`
C03	`03`	`X`	`SPA`	`@0 Antiparkinsoniano @5 05`
C03	`04`	`X`	`FRE`	`@0 Carbidopa @2 NK @2 FR @5 07`
C03	`04`	`X`	`ENG`	`@0 Carbidopa @2 NK @2 FR @5 07`
C03	`04`	`X`	`SPA`	`@0 Carbidopa @2 NK @2 FR @5 07`
C03	`05`	`X`	`FRE`	`@0 Bromocriptine @2 NK @2 FR @5 10`
C03	`05`	`X`	`ENG`	`@0 Bromocriptine @2 NK @2 FR @5 10`
C03	`05`	`X`	`SPA`	`@0 Bromocriptina @2 NK @2 FR @5 10`
C03	`06`	`X`	`FRE`	`@0 Arrêt traitement @5 13`
C03	`06`	`X`	`ENG`	`@0 Treatment withdrawal @5 13`
C03	`06`	`X`	`SPA`	`@0 Paro tratamiento @5 13`
C03	`07`	`X`	`FRE`	`@0 Chimiothérapie @5 16`
C03	`07`	`X`	`ENG`	`@0 Chemotherapy @5 16`
C03	`07`	`X`	`SPA`	`@0 Quimioterapia @5 16`
C03	`08`	`X`	`FRE`	`@0 Evolution @5 17`
C03	`08`	`X`	`ENG`	`@0 Evolution @5 17`
C03	`08`	`X`	`SPA`	`@0 Evolución @5 17`
C03	`09`	`X`	`FRE`	`@0 Homme @5 20`
C03	`09`	`X`	`ENG`	`@0 Human @5 20`
C03	`09`	`X`	`SPA`	`@0 Hombre @5 20`
C03	`10`	`X`	`FRE`	`@0 Ergot dérivé @5 31`
C03	`10`	`X`	`ENG`	`@0 Ergot derivatives @5 31`
C03	`10`	`X`	`SPA`	`@0 Ergot derivado @5 31`
C07	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 37`
C07	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 38`
C07	`02`	`X`	`ENG`	`@0 Central nervous system disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Encéphale pathologie @5 39`
C07	`03`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`03`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`04`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`05`	`X`	`FRE`	`@0 Maladie dégénérative @5 41`
C07	`05`	`X`	`ENG`	`@0 Degenerative disease @5 41`
C07	`05`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 41`
N21				`@1 185`

Format Inist (serveur)

NO :	PASCAL 00-0269467 INIST
ET :	Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's Disease
AU :	HAUSER (R. A.); KOLLER (W. C.); HUBBLE (J. P.); MALAPIRA (T.); BUSENBARK (K.); OLANOW (C. W.)
AF :	University of South Florida/Tampa, Florida/Etats-Unis (1 aut., 4 aut.); University of Miami/Miami, Florida/Etats-Unis (2 aut.); Ohio State University/Columbus, Ohio/Etats-Unis (3 aut.); University of Kansas/Kansas City, Kansas/Etats-Unis (5 aut.); Mount Sinai School of Medicine/New York, NY/Etats-Unis (6 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2000; Vol. 15; No. 3; Pp. 485-489; Bibl. 17 ref.
LA :	Anglais
EA :	Putative neuroprotective agents for Parkinson's disease can be assessed in untreated patients using progression of clinical disability as an index of disease progression. To avoid the confound associated with symptomatic therapy, progression of the underlying disease can be assessed by evaluating the progression of clinical disability from an untreated baseline to a final visit following wash-out of symptomatic medication. In this type of analysis it is critical to use a wash-out of sufficient duration to ensure elimination of symptomatic effects. To assess the time course of resolution of symptomatic effects, we evaluated 31 patients at days 1, 8, and 15 following discontinuation of levodopa/carbidopa and bromocriptine. Mean total Unified Parkinson's Disease Rating Scale scores (± standard error) increased (worsened) by 7.4 ± 1.5 from day 1 to day 15 (p <0.0001), 4.5 ± 1.2 from day I to day 8 (p = 0.0009), and 2.9 ± 1.0 from day 8 to day 15 (p = 0.01). We conclude that a wash-out of at least 2 weeks is required to eliminate the symptomatic effects of levodopa/carbidopa and bromocriptine in patients with early Parkinson's disease.
CC :	002B02B06; 002B17G
FD :	Parkinson maladie; Lévodopa; Antiparkinsonien; Carbidopa; Bromocriptine; Arrêt traitement; Chimiothérapie; Evolution; Homme; Ergot dérivé
FG :	Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative
ED :	Parkinson disease; Levodopa; Antiparkinson agent; Carbidopa; Bromocriptine; Treatment withdrawal; Chemotherapy; Evolution; Human; Ergot derivatives
EG :	Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease
SD :	Parkinson enfermedad; Levodopa; Antiparkinsoniano; Carbidopa; Bromocriptina; Paro tratamiento; Quimioterapia; Evolución; Hombre; Ergot derivado
LO :	INIST-20953.354000087348900090
ID :	00-0269467

Links to Exploration step

Pascal:00-0269467

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's Disease</title>
<author><name sortKey="Hauser, R A" sort="Hauser, R A" uniqKey="Hauser R" first="R. A." last="Hauser">R. A. Hauser</name>
<affiliation><inist:fA14 i1="01"><s1>University of South Florida</s1>
<s2>Tampa, Florida</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Koller, W C" sort="Koller, W C" uniqKey="Koller W" first="W. C." last="Koller">W. C. Koller</name>
<affiliation><inist:fA14 i1="02"><s1>University of Miami</s1>
<s2>Miami, Florida</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hubble, J P" sort="Hubble, J P" uniqKey="Hubble J" first="J. P." last="Hubble">J. P. Hubble</name>
<affiliation><inist:fA14 i1="03"><s1>Ohio State University</s1>
<s2>Columbus, Ohio</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Malapira, T" sort="Malapira, T" uniqKey="Malapira T" first="T." last="Malapira">T. Malapira</name>
<affiliation><inist:fA14 i1="01"><s1>University of South Florida</s1>
<s2>Tampa, Florida</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Busenbark, K" sort="Busenbark, K" uniqKey="Busenbark K" first="K." last="Busenbark">K. Busenbark</name>
<affiliation><inist:fA14 i1="04"><s1>University of Kansas</s1>
<s2>Kansas City, Kansas</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Olanow, C W" sort="Olanow, C W" uniqKey="Olanow C" first="C. W." last="Olanow">C. W. Olanow</name>
<affiliation><inist:fA14 i1="05"><s1>Mount Sinai School of Medicine</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">00-0269467</idno>
<date when="2000">2000</date>
<idno type="stanalyst">PASCAL 00-0269467 INIST</idno>
<idno type="RBID">Pascal:00-0269467</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002C07</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's Disease</title>
<author><name sortKey="Hauser, R A" sort="Hauser, R A" uniqKey="Hauser R" first="R. A." last="Hauser">R. A. Hauser</name>
<affiliation><inist:fA14 i1="01"><s1>University of South Florida</s1>
<s2>Tampa, Florida</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Koller, W C" sort="Koller, W C" uniqKey="Koller W" first="W. C." last="Koller">W. C. Koller</name>
<affiliation><inist:fA14 i1="02"><s1>University of Miami</s1>
<s2>Miami, Florida</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hubble, J P" sort="Hubble, J P" uniqKey="Hubble J" first="J. P." last="Hubble">J. P. Hubble</name>
<affiliation><inist:fA14 i1="03"><s1>Ohio State University</s1>
<s2>Columbus, Ohio</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Malapira, T" sort="Malapira, T" uniqKey="Malapira T" first="T." last="Malapira">T. Malapira</name>
<affiliation><inist:fA14 i1="01"><s1>University of South Florida</s1>
<s2>Tampa, Florida</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Busenbark, K" sort="Busenbark, K" uniqKey="Busenbark K" first="K." last="Busenbark">K. Busenbark</name>
<affiliation><inist:fA14 i1="04"><s1>University of Kansas</s1>
<s2>Kansas City, Kansas</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Olanow, C W" sort="Olanow, C W" uniqKey="Olanow C" first="C. W." last="Olanow">C. W. Olanow</name>
<affiliation><inist:fA14 i1="05"><s1>Mount Sinai School of Medicine</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2000">2000</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson agent</term>
<term>Bromocriptine</term>
<term>Carbidopa</term>
<term>Chemotherapy</term>
<term>Ergot derivatives</term>
<term>Evolution</term>
<term>Human</term>
<term>Levodopa</term>
<term>Parkinson disease</term>
<term>Treatment withdrawal</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Lévodopa</term>
<term>Antiparkinsonien</term>
<term>Carbidopa</term>
<term>Bromocriptine</term>
<term>Arrêt traitement</term>
<term>Chimiothérapie</term>
<term>Evolution</term>
<term>Homme</term>
<term>Ergot dérivé</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Putative neuroprotective agents for Parkinson's disease can be assessed in untreated patients using progression of clinical disability as an index of disease progression. To avoid the confound associated with symptomatic therapy, progression of the underlying disease can be assessed by evaluating the progression of clinical disability from an untreated baseline to a final visit following wash-out of symptomatic medication. In this type of analysis it is critical to use a wash-out of sufficient duration to ensure elimination of symptomatic effects. To assess the time course of resolution of symptomatic effects, we evaluated 31 patients at days 1, 8, and 15 following discontinuation of levodopa/carbidopa and bromocriptine. Mean total Unified Parkinson's Disease Rating Scale scores (± standard error) increased (worsened) by 7.4 ± 1.5 from day 1 to day 15 (p <0.0001), 4.5 ± 1.2 from day I to day 8 (p = 0.0009), and 2.9 ± 1.0 from day 8 to day 15 (p = 0.01). We conclude that a wash-out of at least 2 weeks is required to eliminate the symptomatic effects of levodopa/carbidopa and bromocriptine in patients with early Parkinson's disease.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>15</s2>
</fA05>
<fA06><s2>3</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's Disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>HAUSER (R. A.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>KOLLER (W. C.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>HUBBLE (J. P.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>MALAPIRA (T.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>BUSENBARK (K.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>OLANOW (C. W.)</s1>
</fA11>
<fA14 i1="01"><s1>University of South Florida</s1>
<s2>Tampa, Florida</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>University of Miami</s1>
<s2>Miami, Florida</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Ohio State University</s1>
<s2>Columbus, Ohio</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>University of Kansas</s1>
<s2>Kansas City, Kansas</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Mount Sinai School of Medicine</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA20><s1>485-489</s1>
</fA20>
<fA21><s1>2000</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000087348900090</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2000 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>17 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>00-0269467</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Putative neuroprotective agents for Parkinson's disease can be assessed in untreated patients using progression of clinical disability as an index of disease progression. To avoid the confound associated with symptomatic therapy, progression of the underlying disease can be assessed by evaluating the progression of clinical disability from an untreated baseline to a final visit following wash-out of symptomatic medication. In this type of analysis it is critical to use a wash-out of sufficient duration to ensure elimination of symptomatic effects. To assess the time course of resolution of symptomatic effects, we evaluated 31 patients at days 1, 8, and 15 following discontinuation of levodopa/carbidopa and bromocriptine. Mean total Unified Parkinson's Disease Rating Scale scores (± standard error) increased (worsened) by 7.4 ± 1.5 from day 1 to day 15 (p <0.0001), 4.5 ± 1.2 from day I to day 8 (p = 0.0009), and 2.9 ± 1.0 from day 8 to day 15 (p = 0.01). We conclude that a wash-out of at least 2 weeks is required to eliminate the symptomatic effects of levodopa/carbidopa and bromocriptine in patients with early Parkinson's disease.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02B06</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Lévodopa</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Levodopa</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Levodopa</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Carbidopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Carbidopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Carbidopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Bromocriptine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Bromocriptine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Bromocriptina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Arrêt traitement</s0>
<s5>13</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Treatment withdrawal</s0>
<s5>13</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Paro tratamiento</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>16</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>16</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>16</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Evolution</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Evolution</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Evolución</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Ergot dérivé</s0>
<s5>31</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Ergot derivatives</s0>
<s5>31</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Ergot derivado</s0>
<s5>31</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fN21><s1>185</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 00-0269467 INIST</NO>
<ET>Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's Disease</ET>
<AU>HAUSER (R. A.); KOLLER (W. C.); HUBBLE (J. P.); MALAPIRA (T.); BUSENBARK (K.); OLANOW (C. W.)</AU>
<AF>University of South Florida/Tampa, Florida/Etats-Unis (1 aut., 4 aut.); University of Miami/Miami, Florida/Etats-Unis (2 aut.); Ohio State University/Columbus, Ohio/Etats-Unis (3 aut.); University of Kansas/Kansas City, Kansas/Etats-Unis (5 aut.); Mount Sinai School of Medicine/New York, NY/Etats-Unis (6 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2000; Vol. 15; No. 3; Pp. 485-489; Bibl. 17 ref.</SO>
<LA>Anglais</LA>
<EA>Putative neuroprotective agents for Parkinson's disease can be assessed in untreated patients using progression of clinical disability as an index of disease progression. To avoid the confound associated with symptomatic therapy, progression of the underlying disease can be assessed by evaluating the progression of clinical disability from an untreated baseline to a final visit following wash-out of symptomatic medication. In this type of analysis it is critical to use a wash-out of sufficient duration to ensure elimination of symptomatic effects. To assess the time course of resolution of symptomatic effects, we evaluated 31 patients at days 1, 8, and 15 following discontinuation of levodopa/carbidopa and bromocriptine. Mean total Unified Parkinson's Disease Rating Scale scores (± standard error) increased (worsened) by 7.4 ± 1.5 from day 1 to day 15 (p <0.0001), 4.5 ± 1.2 from day I to day 8 (p = 0.0009), and 2.9 ± 1.0 from day 8 to day 15 (p = 0.01). We conclude that a wash-out of at least 2 weeks is required to eliminate the symptomatic effects of levodopa/carbidopa and bromocriptine in patients with early Parkinson's disease.</EA>
<CC>002B02B06; 002B17G</CC>
<FD>Parkinson maladie; Lévodopa; Antiparkinsonien; Carbidopa; Bromocriptine; Arrêt traitement; Chimiothérapie; Evolution; Homme; Ergot dérivé</FD>
<FG>Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative</FG>
<ED>Parkinson disease; Levodopa; Antiparkinson agent; Carbidopa; Bromocriptine; Treatment withdrawal; Chemotherapy; Evolution; Human; Ergot derivatives</ED>
<EG>Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease</EG>
<SD>Parkinson enfermedad; Levodopa; Antiparkinsoniano; Carbidopa; Bromocriptina; Paro tratamiento; Quimioterapia; Evolución; Hombre; Ergot derivado</SD>
<LO>INIST-20953.354000087348900090</LO>
<ID>00-0269467</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002C07 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 002C07 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:00-0269467
   |texte=   Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's Disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's Disease

Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's Disease

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri